REGN · News · 20261112N
Competition and Market Share
REGENERON PHARMACEUTICALS, INC. · 2026-11-12 · Importance 20 · Surprise 24
A report on Regeneron’s ophthalmology portfolio said Eylea HD is gaining traction while legacy Eylea sales face headwinds. It attributed Eylea HD’s uptake to steady label expansions. The article also cited solid demand for Eylea HD and higher Dupixent profit-sharing as factors that helped mitigate the decline in Eylea sales.
Key facts
- Regeneron's Eylea HD was gaining traction, supported by steady label expansions, while Eylea faced headwinds. source